Carisma Therapeutics Ownership | Who Owns Carisma Therapeutics?
Carisma Therapeutics Ownership Summary
Carisma Therapeutics is owned by 0.12% institutional investors, 26.56% insiders, and 73.32% retail investors. Merck is the largest institutional shareholder, holding 3.53% of CARM shares.
CARM Ownership Benchmark
| Type | Name | % Inst | % Insiders | % Retail |
|---|---|---|---|---|
| Stock | Carisma Therapeutics | 0.12% | 26.56% | 73.32% |
| Sector | Healthcare Stocks | 232.52% | 10.72% | -143.24% |
| Industry | Biotech Stocks | 384.56% | 10.59% | -295.14% |
Institutional Shareholders
Top Institutional Shareholders by Total Shares
| Holder | Shares | % Holding | Value |
|---|---|---|---|
| Merck | 1.47M | 3.53% | $403.67K |
| Northern trust | 55.04K | 0.13% | $15.08K |
| Empowered funds | 30.99K | 0.07% | $1.33K |
| Bridgeway capital management | 30.99K | 0.07% | $8.49K |
| Virtu financial | 22.85K | 0.05% | $6.00K |
| Baader bank aktiengesellschaft | 19.52K | 0.05% | $517.00 |
| Two sigma securities | 12.83K | 0.03% | $3.52K |
| Union bancaire privee, ubp sa | 785.00 | 0.00% | $28.00 |
| Ifp advisors | 206.00 | 0.00% | $9.00 |
| Org partners | 200.00 | 0.00% | $8.00 |
Top Institutional Shareholders by % of Total Assets
| Holder | Shares | % Assets | Value |
|---|---|---|---|
| Merck | 1.47M | 0.18% | $403.67K |
| Two sigma securities | 12.83K | 0.00% | $3.52K |
| Virtu financial | 22.85K | 0.00% | $6.00K |
| Bridgeway capital management | 30.99K | 0.00% | $8.49K |
| Renaissance | - | - | - |
| Barclays | - | - | - |
| Ifp advisors | 206.00 | - | $9.00 |
| Carolina wealth advisors | - | - | - |
| Advisor group | 142.00 | - | $29.00 |
| Baader bank aktiengesellschaft | 19.52K | - | $517.00 |
Top Buyers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Virtu financial | 22.85K | 0.00% | 22.85K |
| Baader bank aktiengesellschaft | 19.52K | - | 19.52K |
| Union bancaire privee, ubp sa | 785.00 | - | 250.00 |
| Advisor group | 142.00 | - | - |
| Ifp advisors | 206.00 | - | - |
Top Sellers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Aju ib investment | - | - | -718.33K |
| Barclays | - | - | -549.30K |
| Vanguard group | - | - | -350.32K |
| Blackrock funding, inc. /de | - | - | -336.79K |
| Renaissance | - | - | -293.69K |
New Positions
| Holder | Shares | % Assets | Change | Value |
|---|---|---|---|---|
| Virtu financial | 22.85K | 0.00% | 22.85K | $6.00K |
Sold Out
| Holder | Change |
|---|---|
| Harbour investments | -37.00 |
| Raymond james financial | -75.00 |
| Sbi securities | -107.00 |
| Carolina wealth advisors | -150.00 |
| Peoples bank/ks | -250.00 |
Institutional Ownership Trends
| Date | Holdings | Change % | Shares | Change % | Ownership | Change % | Increased Position | Change % | Decreased Position | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| Dec 31, 2025 | 5 | -83.87% | 51,694 | -98.32% | - | 0.23% | 2 | -60.00% | - | -100.00% |
| Sep 30, 2025 | 30 | -6.25% | 3,075,840 | -22.45% | 7 | 8.16% | 5 | -44.44% | 4 | -20.00% |
| Jun 30, 2025 | 34 | -2.86% | 3,982,439 | -2.93% | 9 | 9.78% | 10 | -28.57% | 6 | - |
| Mar 31, 2025 | 36 | - | 5,576,157 | 16.58% | 13 | 10.13% | 14 | -6.67% | 6 | -14.29% |
| Dec 31, 2024 | 38 | 2.70% | 4,888,967 | -6.07% | 11 | 7.50% | 16 | 45.45% | 7 | -41.67% |
Recent Insider Transactions
| Date | Name | Role | Activity | Value |
|---|---|---|---|---|
| Oct 07, 2025 | Klichinsky Michael | Chief Scientific Officer | Sell | $14.48K |
| Oct 01, 2025 | Klichinsky Michael | Chief Scientific Officer | Sell | $42.41K |
| Oct 02, 2025 | Klichinsky Michael | Chief Scientific Officer | Sell | $50.86K |
| Oct 03, 2025 | Klichinsky Michael | Chief Scientific Officer | Sell | $31.08K |
Insider Transactions Trends
| Date | Buy | Sell |
|---|---|---|
| 2025 Q4 | - | 4 |
| 2025 Q1 | - | - |
| 2024 Q4 | - | - |
| 2024 Q3 | - | - |
| 2024 Q2 | - | - |
CARM Ownership FAQ
Try Tickergate Pro Free
Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)
Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis
Discover trending investment themes
Find your next best investment
Research stocks using tools